Other News To Note
Wednesday, February 22, 2012
Cellartis AB, of Gothenburg, Sweden, a division of Cellectis SA, said it will participate in the €2 billion (US$2.69 billion) Innovative Medicines Initiative (IMI), a public-private European initiative to speed the development of new therapeutics. The IMI is supporting collaborative research projects, including an initial effort to develop a preclinical liver test system that surpasses the predictive power of the drug-induced liver injury (DILI) test.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.